Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Stock Information for Enveric Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Enveric Biosciences Inc.

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2026"
Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates
Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results
Enveric Biosciences Announces Reverse Stock Split
Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
Enveric Biosciences to Explore Digital Asset Treasury Opportunities
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.